Note: This section contains information in English only.On Wednesday, Alexion Pharmaceuticals stated it would acquire the privately-owned biotech firm Syntimmune in a deal valuing the company at about $1.2B, boosting its portfolio of drug treatments for rare disorders.
Wed, 26 Sep 2018 14:57:00 GMT
Source: Dukascopy Bank SA